Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin. Academic Article uri icon

Overview

abstract

  • A phase II trial of carboplatin was conducted in 22 patients with advanced germ cell tumors refractory to cisplatin-based chemotherapy. Twenty of 22 patients were evaluable for toxicity and response. Two partial responses and one minor response were seen. The major toxic effect was myelosuppression. Carboplatin has antitumor activity in patients with advanced germ cell tumors refractory to cisplatin, and phase II and III studies of combination chemotherapy are indicated.

publication date

  • February 1, 1987

Research

keywords

  • Neoplasms, Germ Cell and Embryonal
  • Organoplatinum Compounds

Identity

Scopus Document Identifier

  • 0023092831

PubMed ID

  • 3026627

Additional Document Info

volume

  • 71

issue

  • 2